Anne Marie Robertson
Executive Vice President, EVERSANA ONCOLOGY Commercialization™
Expertise:
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional teams. Specifically, Anne Marie has a record of successfully launching oncology therapies, such as Erbitux, Inlyta and Akynzeo, as well as developing new indications for in-market therapies. Her ability to set launch strategy and create science-based differentiation allows Anne Marie to leverage marketing strategies for clients globally while establishing and meeting launch metrics and driving overall brand value.
Anne Marie has an MBA from Baruch College of the City University of New York and a Bachelor of Science in biology from Rensselaer Polytechnic Institute. Early in her career Anne Marie was a U.S. Peace Corps Volunteer in Central Africa.
Articles by Anne Marie Robertson
Redefining CAR-T Access: Strategic Implications of the FDA’s REMS Decision
The FDA’s removal of REMS requirements for BCMA- and CD19-directed CAR-T therapies marks a pivotal regulatory milestone—reducing administrative burdens and opening the door to broader patient access. But the real opportunity lies in how manufacturers respond to a growing pipeline of CAR-T candidates competing for limited treatment center capacity. As clinical efficacy alone is no […]
Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance
Discover the latest insights from the FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this article, our EVERSANA ONCOLOGY experts explore how to align strategy with compliance while maximizing the impact of data across […]
Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses
The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA ONCOLOGY’s experts explore how to align strategy with compliance while maximizing the impact of data across a variety of scientifically sound […]
Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections […]
Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections Solutions […]
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections […]
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy cancer cells. Historically limited to later lines of treatment due to potential side effects and the need for individualized […]
Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024
Every year, the European Society for Medical Oncology (ESMO) brings together experts from pharma, research and advocacy organizations, and healthcare providers (HCPs) to hear about the year’s biggest oncology breakthroughs. With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and […]
FDA Guidance and Considerations for Scientific Exchange Communication Strategies
In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk and opportunity for more informative conversations between pharmaceutical manufacturer representatives and healthcare providers (HCPs) regarding the care of individual […]
Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact
The oncology market is experiencing rapid growth, driven by innovations in therapies like biomarker-directed and cell-and-gene therapies. These advancements contribute to improved overall and progression-free survival in various cancer types. However, challenges arise from accelerated approvals and meeting confirmatory trials, leading to withdrawals of oncology drugs. With the increasing complexity of data, navigating regulatory intricacies, […]
Transforming Pharmaceutical Commercialization: Eight Key Insights for Success
Unlock the keys to successful pharmaceutical commercialization with our latest article: “Transforming Pharmaceutical Commercialization: Eight Key Insights for Success.” This insightful piece explores crucial, actionable strategies to transform your approach to drug launch. Here’s a glimpse of what you’ll discover: Eight Key Insights for Success 1. Tailor Your Team: Learn why scaling your team to […]
Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies
Personalized cancer immunotherapies are emerging as a revolutionary approach to cancer treatment, aiming to provide individualized therapies based on a patient’s specific genetic makeup. The FDA has not yet approved any personalized cancer immunotherapies, creating an intense race within pharma to be the first mover. These therapies have the potential to overcome the limitations of […]
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward
Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented pressure to accelerate their oncology product launch timeline. To add an additional layer of complexity, manufacturers may opt to […]